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Vicriviroc, A Novel CCR5 Inhibitor, is NOT A p-glycoprotein 
Substrate In Vitro
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The CCR5 chemokine receptor is a promising target for
antiretroviral therapy because of its role as a coreceptor for
HIV entry and propagation of infection. Vicriviroc, a small
molecule CCR5 inhibitor being studied in clinical trials, is
well absorbed in rats and monkeys; in vitro studies were
performed with caco-2 cells to determine its bi-directional
permeability and potential as a p-glycoprotein (pGp)
efflux substrate.
Caco-2 cells (passage 60 to 61) were grown for 3 weeks to
confluency and the integrity of the monolayer was con-
firmed by TEER measurements in the presence of vicrivi-
roc (50 to 400 mM). For bi-directional permeability
studies, vicriviroc was placed on either the apical (A) or
basolateral (B) compartment at a concentration of 40 mM
and permeability (n = 3) was determined over 2 hrs with
an LC/MS/MS assay. Total recovery exceeded 85% in all
studies. The passive permeability (A to B) performance of
the caco-2 cell monolayers were confirmed with atenolol
(Pc = 3 ± 1.7 nm/s) and pindolol (Pc = 200 ± 9 nm/s).
Functional expression of pGp was confirmed with the
standard pGp substrate digoxin (bi-directional efflux
ratios: 4- to 10-fold).
Vicriviroc showed high A to B permeability (Pc = 400 ± 4
nm/s) consistent with its high in vivo oral absorption. The
bi-directional efflux ratio of vicriviroc was only 0.6 indi-
cating that it is not a pGp substrate in vitro. These data
suggested that pGp is unlikely to affect the oral absorption
of vicriviroc and that co-administration of vicriviroc with
a pGp inhibitor is unlikely to cause significant drug-drug
interactions.
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